Depression News and Research

Latest Depression News and Research

Depression raises risks of advanced and severe complications from diabetes

Depression raises risks of advanced and severe complications from diabetes, according to a prospective study of Group Health primary-care patients in western Washington. These complications include kidney failure or blindness, the result of small vessel damage, as well as major vessel problems leading to heart attack or stroke.

28 Jan 2010

Regular exercise and drinking tea may reduce depression in breast cancer patients

Breast cancer patients who exercise and drink tea on a regular basis may be less likely to suffer from depression than other patients, according to a new study led by Xiao Ou Shu, M.D., Ph.D., professor of Medicine, Vanderbilt-Ingram Cancer Center. Xiaoli Chen, M.D., a post-doctoral fellow, was first author of the study published in the January issue of the Journal of Clinical Oncology.

28 Jan 2010

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca's Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources' market forecast for the indication. As previously forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.

28 Jan 2010

Study finds sexual minority youth are bullied more than heterosexual youth

The act and victimization of bullying continues to be a problem among today's youth. While many children are experiencing this form of violence, it is more prevalent in children that are different from the social norm.

28 Jan 2010

Patients with epilepsy who take Ginkgo herbal medicines face increased risk of seizures

Restrictions should be placed on the use of Ginkgo biloba (G. biloba) - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes.

28 Jan 2010

Electrode devices emerge as potential stimulation treatments for depression

Approximately ten to thirty percent of patients with depression do not respond to drug treatments commonly used for the disorder, and this has spurred a search for alternatives. According to Kalorama Information's report "Electrical and Magnetic Neurostimulation," electrode devices that stimulate nerves have emerged as a solution and there is competition among notable device companies to provide the most effective stimulator.

28 Jan 2010

Discovery could help improve diagnosis and treatment for anxiety disorders

Draw a map of the brain when fear and anxiety are involved, and the amygdala-the brain's almond-shaped center for panic and fight-or-flight responses-looms large.

27 Jan 2010

Mayo Clinic achieves new levels of excellence in service to humanity

Mayo Clinic announced today that it raised $1.35 billion in its first comprehensive fundraising campaign, surpassing the goal of $1.25 billion.

27 Jan 2010

Chronic insomnia may be associated with reduced cortical volume, says study

Chronic and severely stressful situations, like those connected to depression and posttraumatic stress disorder, have been associated with smaller volumes in "stress sensitive" brain regions, such as the cingulate region of the cerebral cortex and the hippocampus, a brain region involved in memory formation.

27 Jan 2010

Burnham renamed to honor T. Denny Sanford's support

Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute's leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute. This is the second gift Sanford has made to Burnham. In 2007, he directed $20 million through Sanford Health to create the Sanford Children's Health Research Center at Burnham.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Researching treatments shows paths to health savings

An orthopedic surgeon in Sacramento became suspicious of a new therapy that helps tendons heal by injecting platelet-rich plasma into joints, The Sacramento Bee reports. So, he decided to do a test. It turned out, his patients outcomes were no different when he used the platelet-rich plasma therapy as when he didn't. The plasma treatment costs hundreds of dollars more per patient.

27 Jan 2010

Scott & White conducts DBS research for Parkinson's patients

At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.

27 Jan 2010

Testing DBS for treating severe long-term depression

Bewernick and colleagues administered DBS treatment in ten patients with severe long-term depression who had not responded to multiple other antidepressant treatments, including psychotherapy, drug treatments and electroconvulsive treatment. After one year of DBS, all patients showed some improvement, and half of them experienced significant improvement in their symptoms of depression, astonishing considering they had not responded to any prior antidepressant treatment. In addition, the patients showed reduced ratings of anxiety and had only minor side effects. Importantly, none of their overall brain functioning was impaired by the DBS treatment.

27 Jan 2010

Insertion of tiny heart pump without surgery

Cardiologists at the University of Illinois Medical Center at Chicago are leading the Midwest in offering improved treatment options to patients, from the most advanced techniques in angioplasty, to lowering the amount of radiation exposure during heart scans, to opening an innovative clinic that treats heart disease and depression together.

23 Jan 2010

UK Gill Heart Institute offers individualized fitness program for heart patients

How do you change health habits among a population with some of the highest heart disease rates in the world? Tackling heart disease in Kentucky - an epicenter of heart health problems - the University of Kentucky Gill Heart Institute Cardiac Rehabilitation Program is helping high-risk patients make radical, lasting changes to improve their heart health.

23 Jan 2010

Ampyra receives FDA approval for improving walking in MS patients

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

23 Jan 2010

NIH awards grants to develop new tobacco-related drug therapies

Four scientists at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center have been awarded more than $2.2 million from the National Institutes of Health (NIH) to research the effects of nicotine and develop new tobacco-related drug therapies.

22 Jan 2010

Update on the status of Somaxon Pharmaceuticals' NDA for Silenor provided

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today provided an update on the status of its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

22 Jan 2010

MaMayo Clinic experts available to discuss health issues and concerns related to Olympic Games

Mayo Clinic's medical experts are sources of in-depth expertise and commentary about health issues and background related to the Olympic Games and Olympians. Below is a sampling of Mayo Clinic experts available to discuss numerous topics related to the Olympic Games, including concussions, performance enhancing drugs, sports psychology, joint injuries, etc. Mayo has satellite capability for broadcast requests.

21 Jan 2010